OSE Immunotherapeutics Reports Positive Tedopi Phase 2 Results
Nantes, France — October 29, 2026 OSE Immunotherapeutics SA reported final positive results from its Combi-TED Phase 2 randomized...
overall survival
Advertisement
Genmab Reports Positive Phase 3 Petosemtamab Combination Results in Head and Neck Cancer
Copenhagen, Denmark — October 28, 2026 Genmab A/S announced positive topline results from the first interim analysis of its...
Immuneering Presents Atebimetinib Pancreatic Cancer Data at AACR
NEW YORK — September 28, 2026 Immuneering Corporation presented new data at the 2026 AACR Conference on Pancreatic Cancer...
AstraZeneca Gains US Priority Review for IMFINZI in MIBC
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
Advertisements
Corcept Gains Positive CHMP Opinion for Lifyorli in Ovarian Cancer
REDWOOD CITY, Calif. — September 18, 2026 Corcept Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products...
Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Advertisement
